Search Results 1981-1990 of 18746 for Relapse
Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND. Rare ...
- Relapsed, locally-advanced or metastatic colorectal or pancreatic cancer, sqNSCLC, or SCCHN participants who are not candidates for standard therapy ...
Mantle cell lymphoma; Follicular lymphoma; Multiple myeloma. People who have relapsed or refractory disease may be eligible for CAR-T cell therapy. Possible ...
Also, to improve disease control by decreasing the number of spinal relapses for patients who achieve a complete response (CR) or partial response (PR) and ...
This medicine will not cure MS, but it may slow some of the disabling effects and decrease the number of relapses of the disease. This medicine is to be ...
... relapsed refractory T-cell lymphoma. Blood Adv. 2022 Jun 14; 6 (11):3268-3279. View PubMed; Peng KW, Carey T, Lech P, Vandergaast R, Munoz-Alia MA ...
I relapsed. I was stuck in a loop of depression, isolation and bingeing, and desperate for any quick fix to make me feel normal. Giving up seemed like a ...
... relapsed NSCLC. Participants in both Phase 1 and 2 will be selected for treatment with \[177Lu\]Lu FAP 2286 based on \[68Ga\]Ga FAP 2286 imaging for ...
History of relapsing (at least 1 confirmed EGPA relapse within last 2 years and \> 12 weeks prior to screening), or refractory (failure to attain remission ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.